OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Discovery is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis	213
Advances in cryo-electron microscopy (cryoEM) for structure-based drug discovery	117
Training recurrent neural networks as generative neural networks for molecular structures: how does it impact drug discovery?	105
Artificial intelligence in early drug discovery enabling precision medicine	86
Identification of the abnormalities in astrocytic functions as potential drug targets for neurodegenerative disease	62
Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis	61
Overcoming multidrug resistance through targeting ABC transporters: lessons for drug discovery	52
The current progress in the use of boron as a platform for novel antiviral drug design	50
Reality check: lipid-oligonucleotide conjugates for therapeutic applications	50
Advances with the discovery and development of novel sigma 1 receptor antagonists for the management of pain	47
The discovery and development of novel treatment strategies for filoviruses	43
The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies	40
Advances in the discovery of drugs that treat pulmonary arterial hypertension	40
1,2,3,4-Tetrahydroisoquinoline (THIQ) as privileged scaffold for anticancer de novo drug design	39
The problem of antimalarial resistance and its implications for drug discovery	39
Advances in ion channel high throughput screening: where are we in 2023?	38
What is the future of click chemistry in drug discovery and development?	38
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease	37
Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities	33
The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer	32
Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics	31
Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure	29
Molecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins	28
Opportunities and challenges in new HIV therapeutic discovery: what is the next step?	27
Maximizing the integration of virtual and experimental screening in hit discovery	27

Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer	27
What is an ideal antibiotic and what does this mean for future drug discovery and design?	26